Gefitinib is an advanced oral targeted therapy used primarily for treating non-small cell lung cancer (NSCLC). It belongs to the class of epidermal growth factor receptor (EGFR) inhibitors, which work by blocking cancer cell growth and proliferation. Since its approval, Gefitinib has played a crucial role in lung cancer treatment, especially for patients with EGFR mutations.
With an increasing...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Romaian
Portuguese (Brazil)
Greek